[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-352651-105":59,"doc-detail-352651-en":134},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":127,"head_meta":129,"extra_data":131,"updated_unix":133},105,"en","therapeutic-monoclonal-antibodies-repurposing-in-oncology-via-imgtmab-kg-embeddings-research-open-access","Therapeutic monoclonal antibodies repurposing in oncology via IMGT/mAb-KG embeddings - Research Open Access","","Cancer causes about 9.7 million deaths in 2022, and therapeutic monoclonal antibodies (mAbs) are pursued to reduce side effects compared with conventional chemotherapy or radiotherapy. The IMGT system provides standardized mAb data resources, including IMGT/mAb-DB and the newer IMGT/mAb-KG knowledge graph. Yet developing therapeutic mAbs remains costly and slow, so mAb repurposing is explored. Results build an oncology-focused knowledge graph embedding workflow and support hypothesis generation.",{"@graph":69,"@context":126},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/therapeutic-monoclonal-antibodies-repurposing-in-oncology-via-imgtmab-kg-embeddings-research-open-access/352651/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/therapeutic-monoclonal-antibodies-repurposing-in-oncology-via-imgtmab-kg-embeddings-research-open-access/352651.png","ImageObject",300,407,{"name":92,"@type":93},"\tCallum ","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-23","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":34},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118,122],{"name":109,"@type":110,"acceptedAnswer":111},"What challenge does the study address in therapeutic monoclonal antibody development?","Question",{"text":112,"@type":113},"Therapeutic mAbs development is time-consuming and financially burdensome, with costs that can reach up to $2.8 billion. The paper targets this bottleneck by accelerating cancer treatment through mAb repurposing.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"Which knowledge graph approach and domain subset are used for hypothesis generation?",{"text":117,"@type":113},"The study leverages a specialized oncology subset of an expert-curated mAb data model, IMGT/mAbOnco-KG, to build an application for scientific hypothesis generation. It evaluates many transductive knowledge graph embedding models to support repurposing predictions.",{"name":119,"@type":110,"acceptedAnswer":120},"What embeddings model performs best and what prediction support is provided?",{"text":121,"@type":113},"BoxE is identified as the superior architecture for capturing asymmetric relations in mAb-target-disease interactions. The accompanying web interface includes trackback support to visualize biological subgraphs that support each prediction.",{"name":123,"@type":110,"acceptedAnswer":124},"What new mAbs does the tool highlight for clinical development?",{"text":125,"@type":113},"The tool identifies two novel mAbs—loncastuximab tesirine and glofitamab—currently undergoing clinical trials for chronic lymphocytic leukemia.","https://schema.org",{"og:url":83,"og:type":128,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":130,"canonical":83},"index,follow",{"doc_id":132,"site_id":62},352651,1790470032,{"code":4,"msg":5,"data":135},{"doc_id":132,"user_id":136,"nickname":92,"user_avatar":137,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":138,"file_id":139,"file_url":140,"file_type":141,"file_size":142,"view_count":34,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":143,"language":144,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":145,"faqs":146,"seo_title":147,"seo_description":67,"update_tm":148,"read_time":149,"preview_page_count":19,"preview_urls":150},137451211410,"https://ap-avatar.wpscdn.com/avatar/2000bb0a9246f588df?x-image-process=image/resize,m_fixed,w_180,h_180&k=1786362646172706240","Sanou etal. BMC Medical Informatics and Decision Making (2026) 26:89  \n[https://doi.org/10.1186/s12911-026-03394-4](https://doi.org/10.1186/s12911-026-03394-4)  \nBMC Medical Informatics and Decision Making  \nRESEARCH Open Access  \nTherapeutic monoclonal antibodies repurposing in oncology via IMGT/mAb-KG embeddings  \nGaoussou Sanou1, Taciana Manso1, Konstantin Todorov2, Véronique Giudicelli1, Patrice Duroux1* and Sofia Kossida 1,3*  \nAbstract  \nBackground Cancer remains one of the leading causes of mortality worldwide, accounting for approximately  \n9.7 million deaths in 2022. Faced with this significant public health challenge, therapeutic monoclonal antibodies (mAbs) have emerged as promising alternatives that may minimize the side effects associated with conventional treatments such as radiotherapy and chemotherapy. To support mAb research and development, IMGT®, the international ImMunoGeneTics information system, has established two standardized data sources namely IMGT/ mAb-DB, a comprehensive database for mAbs, and, more recently, IMGT/mAb-KG, a dedicated knowledge graph formAbs. Despite these advances, the development of therapeutic mAbs remains both time-consuming and financially burdensome—costs can reach up to $2.8 billion. To address this challenge and accelerate cancer treatment, mAb repurposing represents a promising alternative.  \nResults Compared to existing general drug repurposing frameworks, in this study, we leveraged a specialized subset of an expert-curated mAb-specific data model dedicated to the oncology domain IMGT/mAbOnco-KG, to develop a scientific hypothesis generation application for mAb repurposing. We conducted an exhaustive benchmarking of 28 transductive knowledge graph embedding models, identifying BoxE as the superior architecture for capturing asymmetric relations inherent in mAb-target-disease interactions. A user-friendly web interface provides access to the tool, incorporating a novel trackback support allowing researchers to visualize the biological subgraphs supporting each prediction.  \nConclusion Our application demonstrates the potential of transductive knowledge graph embedding techniques in the oncology domain by enabling the repurposing of existing mAbs for new therapeutic uses. Using this tool, we have identified two novel mAbs, loncastuximab tesirine and glofitamab, both currently undergoing clinical trials for the treatment of chronic lymphocytic leukemia. This decision-support tool thus facilitates the discovery of new therapeutic opportunities by effectively repositioning existing mAbs for oncological indications, potentially accelerating the development of cancer therapies and addressing critical public health needs. To handle new clinical indication entities, our future research direction is to build a foundation model in immunogenetics. In addition, due to  \n*Correspondence:  \nPatrice Duroux [patrice.duroux@igh.cnrs.fr](patrice.duroux@igh.cnrs.fr)[ ](patrice.duroux@igh.cnrs.fr)Sofia Kossida [sofia.kossida@igh.cnrs.fr](sofia.kossida@igh.cnrs.fr)  \nFull list of author information is available at the end of the article  \n© The Author(s) 2026. Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the pe","cbCaiawGECsnCkO5","https://ap.wps.com/l/cbCaiawGECsnCkO5","pdf",7364672,21,"English","# Abstract\n## Background\n## Results\n## Conclusion\n# Introduction\n## Cancer burden and immune interactions\n## Role of therapeutic monoclonal antibodies","[{\"question\":\"What challenge does the study address in therapeutic monoclonal antibody development?\",\"answer\":\"Therapeutic mAbs development is time-consuming and financially burdensome, with costs that can reach up to $2.8 billion. The paper targets this bottleneck by accelerating cancer treatment through mAb repurposing.\"},{\"question\":\"Which knowledge graph approach and domain subset are used for hypothesis generation?\",\"answer\":\"The study leverages a specialized oncology subset of an expert-curated mAb data model, IMGT/mAbOnco-KG, to build an application for scientific hypothesis generation. It evaluates many transductive knowledge graph embedding models to support repurposing predictions.\"},{\"question\":\"What embeddings model performs best and what prediction support is provided?\",\"answer\":\"BoxE is identified as the superior architecture for capturing asymmetric relations in mAb-target-disease interactions. The accompanying web interface includes trackback support to visualize biological subgraphs that support each prediction.\"},{\"question\":\"What new mAbs does the tool highlight for clinical development?\",\"answer\":\"The tool identifies two novel mAbs—loncastuximab tesirine and glofitamab—currently undergoing clinical trials for chronic lymphocytic leukemia.\"}]","Therapeutic monoclonal antibodies repurposing in oncology via IMGT/mAb-KG embeddings - Research Open Access | PDF",1790100640,53,[151,155,159,163],{"page_no":8,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/c1880e082e815f225a91de79da233f52.webp",983,1310,{"page_no":14,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/cd54ea6f5fce736dbca4d6751f5f55dd.webp",982,1309,{"page_no":81,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/b6d05c4608a4a1409d84633bb0c56b4a.webp",981,1308,{"page_no":19,"url":164,"width":165,"height":166},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/da32dfac1c987d27cd75bd85a2b92e20.webp",980,1306]